The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford scientists have discovered that cross-linking antigens can overcome sub-type bias in response to multi-strain vaccines and induce patients to have a complete, broad immune response to all included antigens.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford researchers in the Mark Davis Lab have developed a human cell culture system to grow 3D immune organoids within hydrogel structures using limited cellular input that can be adapted to large screening assays for flexible downstream immunological readouts.
Stanford scientists have developed broadly neutralizing antibodies against sarbecoviruses , including SARS-CoV-2 related Clade 1b, SARS-CoV related Clade 1a and Clade 3 viruses, paving the way for future vaccines and therapeutics.
Stanford researchers have developed methods for optimizing peptide vaccines, with candidate peptides against EGFPvIII-expressing glioblastoma and SARS-CoV-2.
Stanford researchers have developed saponin lipid-based nanoparticles in which both toll-like receptor agonists (TLRas) and other potent molecular adjuvants can be encapsulated to improve vaccine potency, increase antibody titers, and induce more robust neutralizing antibody r
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Stanford researchers have developed a framework describing an end-to-end approach that infers experimental properties directly from nucleic acid sequence, using a principled statistical mechanical representation of the structure ensemble.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.
The emergence of SARS-CoV-2 variants during the COVID-19 pandemic has demonstrated a need for broad immunization, such as provided by multivalent vaccines.
Stanford researchers have developed one of the smallest, active translational enhancers that can be adapted to control gene regulation. The translation enhancer is a short RNA stem-loop structure isolated from a Hox gene.
Stanford researchers have found a solution to enhance mRNA translation and stability by harnessing SARS-CoV2 genomic sequences themselves. They discovered that the SARS-CoV2 5' untranslated region (5' UTR) can be repurposed for increased translation and stability of any mRNA.